The sodium-glucose co-transporter-2 (SGLT2) inhibitors, a relatively new oral glucose-lowering drug (GLD) class, have been demonstrated to significantly improve cardiovascular outcomes compared with placebo or other GLDs in patients with T2DM [2–6]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.